Systemic chemotherapy for urothelial transitional cell carcinoma: An overview of toxicityMOULDER, Stacy L; ROTH, Bruce J.Seminars in urologic oncology. 2001, Vol 19, Num 3, pp 194-201, issn 1081-0943Article

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancerARTEAGA, Carlos L; MOULDER, Stacy L; YAKES, F. Michael et al.Seminars in oncology. 2002, Vol 29, Num 3, pp 4-10, issn 0093-7754, SUP11Article

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignanciesFALCHOOK, Gerald S; SIQING FU; KURZROCK, Razelle et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1192-1200, issn 0167-6997, 9 p.Article

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group TrialMOULDER, Stacy; HAILUN LI; MOLIN WANG et al.Breast cancer research and treatment. 2010, Vol 119, Num 3, pp 663-671, issn 0167-6806, 9 p.Article

Targeted inhibition of farnesyltransferase in locally advanced breast cancer : A phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamideSPARANO, Joseph A; MOULDER, Stacy; HOPKINS, Una et al.Journal of clinical oncology. 2006, Vol 24, Num 19, pp 3013-3018, issn 0732-183X, 6 p.Article

A Phase 1 Study of Weekly Everolimus (RAD001) in Combination With Docetaxel in Patients With Metastatic Breast CancerMOULDER, Stacy; GLADISH, Gregory; RIVERA, Edgardo et al.Cancer. 2012, Vol 118, Num 9, pp 2378-2384, issn 0008-543X, 7 p.Article

A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast MalignanciesMORONEY, John W; SCHLUMBRECHT, Matthew P; HELGASON, Thorunn et al.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6840-6846, issn 1078-0432, 7 p.Article

Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G₁ Arrest in Human Breast Cancer Cells and TumorsAKLI, Said; BUI, Tuyen; WINGATE, Hannah et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1179-1190, issn 1078-0432, 12 p.Article

Ethnic Disparities in Adherence to Breast Cancer Survivorship Surveillance CareADVANI, Pragati S; JUN YING; THERIAULT, Richard et al.Cancer. 2014, Vol 120, Num 6, pp 894-900, issn 0008-543X, 7 p.Article

Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast CancerSPARANO, Joseph A; MOULDER, Stacy; MALAFA, Mokenge et al.Clinical cancer research (Print). 2009, Vol 15, Num 8, pp 2942-2948, issn 1078-0432, 7 p.Article

Phase 2 Study of Gemcitabine and Irinotecan in Metastatic Breast Cancer With Correlatives to Determine Topoisomerase I Localization as a Predictor of ResponseMOULDER, Stacy; VALKOV, Nickola; SULLIVAN, Dan et al.Cancer. 2008, Vol 113, Num 10, pp 2646-2654, issn 0008-543X, 9 p.Article

Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid TumorsHONG, David; SAID, Rabih; ROSEN, Lee S et al.Clinical cancer research (Print). 2013, Vol 19, Num 17, pp 4824-4831, issn 1078-0432, 8 p.Article

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I TrialGONZALEZ-ANGULO, Ana M; MERIC-BERNSTAM, Funda; MOULDER, Stacy et al.Clinical cancer research (Print). 2013, Vol 19, Num 19, pp 5474-5484, issn 1078-0432, 11 p.Article

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological ActivityMORONEY, John; SIQING FU; MOULDER, Stacy et al.Clinical cancer research (Print). 2012, Vol 18, Num 20, pp 5796-5805, issn 1078-0432, 10 p.Article

Survival of 1,181 Patients in a Phase IClinic: The MD Anderson Clinical Center for Targeted Therapy ExperienceWHELER, Jennifer; TSIMBERIDOU, Apostolia M; KURZROCK, Razelle et al.Clinical cancer research (Print). 2012, Vol 18, Num 10, pp 2922-2929, issn 1078-0432, 8 p.Article

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumorsMUNSTER, Pamela N; BRITTEN, Carolyn D; TOLCHER, Anthony W et al.Clinical cancer research. 2007, Vol 13, Num 4, pp 1238-1245, issn 1078-0432, 8 p.Article

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast CancerARTEAGA, Carlos L; O'NEILL, Anne; MOULDER, Stacy L et al.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 6277-6283, issn 1078-0432, 7 p.Article

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast CancerMOULDER, Stacy L; HOLMES, Frankie A; TOLCHER, Anthony W et al.Cancer. 2010, Vol 116, Num 4, pp 814-821, issn 0008-543X, 8 p.Article

A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumorsMOULDER, Stacy L; MAHANY, John J; SULLIVAN, Daniel M et al.Clinical cancer research. 2004, Vol 10, Num 21, pp 7127-7135, issn 1078-0432, 9 p.Article

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancerDEAN-COLOMB, Windy; HESS, Kenneth R; HORTOBAGYI, Gabriel N et al.Breast cancer research and treatment. 2013, Vol 137, Num 2, pp 631-636, issn 0167-6806, 6 p.Article

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancersWHELER, Jennifer J; JANKU, Filip; PIHA-PAUL, Sarina A et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 495-501, issn 0344-5704, 7 p.Article

Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast CancerMURTHY, Rashmi K; VARMA, Ankur; BOOSER, Daniel et al.Cancer. 2014, Vol 120, Num 13, pp 1932-1938, issn 0008-543X, 7 p.Article

Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast CancerMOULDER, Stacy L; FRASER SYMMANS, W; ZWIEBEL, James et al.Clinical cancer research (Print). 2008, Vol 14, Num 23, pp 7909-7916, issn 1078-0432, 8 p.Article

Dual Inhibition of the Vascular Endothelial Growth Factor Pathway: A Phase 1 Trial Evaluating Bevacizumab and AZD2171 (Cediranib) in Patients With Advanced Solid TumorsHONG, David S; GARRIDO-LAGUNA, Ignacio; YUEJIN WEN et al.Cancer. 2014, Vol 120, Num 14, pp 2164-2173, issn 0008-543X, 10 p.Article